Korean J Hematol.  2007 Jun;42(2):98-105. 10.5045/kjh.2007.42.2.98.

Hematopoietic Stem Cell Transplantation with Using Multinational Unrelated Donors for Acute Myelogenous Leukemia

• Kim HJ
• Min WS
• Eom KS
• Cho BS
• Kim SY
• Bok JN
• Kim KS
• Min CK
• Lee S
• Cho SG
• Kim DW
• Lee JW
• Kim CC

• KMID: 2083506
• DOI: http://doi.org/10.5045/kjh.2007.42.2.98

Abstract

BACKGROUND: Many AML patients have received hematopoietic stem cell transplantation (HSCT) from HLA-matched unrelated donors. According to many of the previous reports, those patients could achieve long-term, disease-free survival after HSCT from multinational unrelated donors with tolerable transplant-related complications, even when there are HLA-mismatches.
METHODS
We present the results of 35 unrelated hematopoietic stem cell transplantations from multiple international donor banks including the Korean (n=24), and Japan Marrow Donor Program (n=3), the Taiwan Tzu Chi Marrow Donation Registry (n=6), as well as using Caucasian donors from the National Marrow Donor Program (n=2), for the treatment of AML patients.
RESULTS
The median age of patients was 36 (range: 16~53) and the median follow-up duration was 21 months (range: 5~60). Also, the median age of the donors was 28 (range: 20~53). The majority of the patients had intermediate or unfavorable cytogenetic features. The main conditioning regimen we used consisted of cyclophosphamide plus TBI (n=31) with our standard GvHD prophylaxis that contained tacrolimus plus a short course of methotrexate. Some patients (n=10) received an additional two-day course of ATG (thymoglobulin, Sangstat) in addition to the standard regimen. All the transplanted patients achieved engraftment. The incidence of acute GvHD was 42%, and that of chronic GvHD was 56%. Four (11%) patients have relapsed to date. The two-year non-relapse transplant-related mortality was 26%. The estimated probability of DFS and the event-free survival at five-years were 80% and 53%, respectively.
CONCLUSION
These results suggest that multinational unrelated donors HSCT may provide a feasible option for the treatment of high-risk Korean AML patients.

Keyword

Multinational unrelated donor; HSCT; AML; GvHD

MeSH Terms

Bone Marrow
Cyclophosphamide
Cytogenetics
Disease-Free Survival
Follow-Up Studies
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells*
Humans
Incidence
Japan
Leukemia, Myeloid, Acute*
Methotrexate
Mortality
Tacrolimus
Taiwan
Tissue Donors
Unrelated Donors*
Cyclophosphamide
Methotrexate
Tacrolimus

Figure

• 

  Fig. 1 Disease-free survival rate (A) and event-free survival rate (B) of mismatched unrelated donor HSCT from multinational donor registries worldwide.

• 

  Fig. 2 Defined outcomes according to the different donor registries included. Disease-free survival rate (A) and event-free survival rate (B) of mismatched unrelated donor HSCT from multinational donor registries.

Reference

1). Anasetti C., Petersdorf EW., Martin PJ., Woolfrey A., Hansen JA. Improving availability and safety of unrelated donor transplants. Curr Opin Oncol. 2000. 12:121–6.

2). Gratwohl A., Baldomero H., Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant. 2007. 39:71–87.

3). Kodera Y., Morishma Y., Kato S, et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant. 1999. 24:995–1003.

4). Sierra J., Storer B., Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, marrow cell dose. Blood. 1997. 89:4226–35.

5). Sierra J., Storer B., Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000. 26:397–404.

6). Davies SM., Kollman C., Anasetti C, et al. Engraftment and survival after unrelated donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000. 96:4096–102.

7). Petersdorf EW., Malkki M. Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation. Semin Hematol. 2005. 42:76–84.

8). Speiser DE., Tiercy JM., Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood. 1996. 87:4455–62.

9). Petersdorf EW., Gooley TA., Anasetti C, et al. Opti-mazing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998. 92:3515–20.

10). Slovak ML., Kopecky KJ., Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000. 96:4075–83.

11). Park HS., Kim DW., Kim CC, et al. Induction chemotherapy with Idarubicin plus N4-behenoyl-1-b-D-ara-binofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen - a prospective, cooperative multicenter study. Semin He-matol. 1996. 33(Suppl.3):24–9.

12). Miller AB., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981. 47:207–14.

13). Bacigalupo A., Lamparelli T., Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Mi-dollo Osseo (GITMO). Blood. 2001. 98:2942–7.

14). Basara N., Baurmann H., Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant. 2005. 35:1011–8.

15). Elsner HA., DeLuca D., Strub J., Blasczyk R. Histo-Check: rating of HLA class I and II mismatches by an internet-based software tool. Bone Marrow Transplant. 2004. 33:165–9.